Developer docs
API playgroundTry for free, no card

Search company profiles

DeepCure

Full company profile

uuid0000jdw

Namestring
DeepCure
Legal namestring
Deepcure
Websiteurl
deepcure.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

DeepCure is a privately held, Boston-headquartered biotechnology company developing AI-driven small molecule therapeutics for immune and inflammatory diseases. Its integrated platform, branded Inspired Chemistry, combines three proprietary components: PocketExpander, which uses AI plus quantum-mechanical and molecular dynamics simulations to map protein surfaces and identify druggable features on targets without known ligands; MolGen, a deep reinforcement learning system that generates readily synthesizable compounds across millions of building blocks and more than 200 chemical reactions; and DiscoveryHub, a collaborative DMTA workflow layer. The platform is closed-loop with an automated robotic wet lab (the Inspired Chemistry synthesis module, built in partnership with Biosero) that has demonstrated parallel synthesis of nirmatrelvir plus 56 analogs.

The company's pipeline comprises three oral small molecule programs: DC-9476, a third-generation selective BRD4-BD2 inhibitor in IND-enabling studies for rheumatoid arthritis, Still's disease, and hidradenitis suppurativa; DC-15442, an oral STAT6 inhibitor named as a development candidate in June 2025 for asthma and atopic dermatitis with preclinical efficacy comparable to dupilumab; and an early-discovery TNFα program for autoimmune indications. DeepCure has also extended its AI stack into knowledge retrieval through a chemistry LLM workflow developed with Google Cloud Platform and CloudWerx, and is generating clinical evidence via a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine.

DeepCure is pre-revenue and pursues a licensing and co-development business model targeting pharmaceutical and biotech partners. The company has raised approximately $70.4 million across seed, Series A, and Series A-1 rounds from investors including Morningside Ventures, TLV Partners, Sapir Venture Partners, Benon Group, and IAG Capital Partners, with Series A proceeds earmarked for establishing operations in Greece and Israel. Its go-to-market is enterprise business development led by CBO Han Lim (formerly CBO of Atomwise), supported by scientific thought leadership at industry conferences and preclinical data publications.

Short descriptiontext

DeepCure is a Boston-based, pre-revenue biotech that uses an integrated AI, physics-based, and automated chemistry platform (PocketExpander, MolGen, DiscoveryHub, Inspired Chemistry) to discover oral small molecule drugs for immune and inflammatory diseases, pursuing a licensing and co-development model with pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule therapeutics, computational chemistry, inflammatory disease pipeline, preclinical immunology
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Biotechnology / AI-driven small molecule drug discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development & Licensing
TypeLicensing Royalties
Description

DeepCure is a pre-revenue biotech company developing a pipeline of novel small molecule drugs for immune and inflammatory diseases. Its primary anticipated revenue streams are out-licensing deals, co-development partnerships with pharmaceutical companies, and ultimately product approvals. The company is advancing DC-9476 (BRD4-BD2 inhibitor, IND-enabling for RA, Still's disease, hidradenitis suppurativa) and DC-15442 (STAT6 inhibitor, development candidate for asthma, atopic dermatitis), with a TNFα program in early discovery.

pixelscientia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DeepCure uses AI and physics-based computational methods to discover and develop novel oral small molecule therapeutics for immune and inflammatory diseases, integrating molecular generation, protein surface mapping, and automated robotic synthesis into a single drug discovery platform. Its current product offering consists of a pipeline of preclinical and IND-enabling drug candidates (DC-9476 for autoimmune diseases, DC-15442 for asthma/atopic dermatitis, and a TNFα program) that it out-licenses or co-develops with pharmaceutical partners. The company does not sell commercial products directly and is pre-revenue, relying on licensing deals, co-development partnerships, and potential acquisitions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • DC-15442 demonstrated nearly 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab in preclinical models
+2 more records
Product overview1 text field

DeepCure is an immunology therapeutics company developing novel small molecule drugs for immune and inflammatory diseases using an integrated AI-powered drug discovery platform called Inspired Chemistry. The platform comprises three core proprietary technologies: PocketExpander (AI and physics-based protein surface mapping), MolGen (reinforcement learning-driven molecular generation), and DiscoveryHub (collaborative research workflow management). The company is advancing a pipeline of oral small molecule therapeutics including DC-9476 (BRD4-BD2 inhibitor for rheumatoid arthritis, IND-enabling stage) and DC-15442 (STAT6 inhibitor for asthma/atopic dermatitis, development candidate stage), with a TNFα program in early discovery. DeepCure operates from Boston with R&D sites in Israel and Greece.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-03
Description

DeepCure completed a pilot program with Google Cloud Platform and CloudWerx (CWX) to build an AI-driven workflow that extracts chemical insights from unstructured literature to answer complex queries on organic chemistry, demonstrating the potential for chemistry LLMs to increase productivity in medicinal chemistry.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-03
Description

CloudWerx collaborated with DeepCure and Google Cloud Platform to build an AI-driven workflow for extracting chemical insights from unstructured literature, demonstrating chemistry LLM capabilities for medicinal chemistry productivity.

3Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-19
Description

DeepCure announced a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine to investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for rheumatoid arthritis patients who do not respond well to current standard of care. The partners will conduct a study using blood samples and joint biopsies from various patient subgroups, focusing on those resistant to current treatments.

pharmaceutical-technology.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-05
Description

DeepCure and Biosero collaborated to establish a fully automated, AI-powered chemistry synthesis platform. This collaboration enabled DeepCure to accelerate synthesis of AI-designed molecules and validate its Inspired Chemistry™ platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI small molecule discovery platform using structure-based deep learning for hit identification and lead optimization. DeepCure's CBO previously served as Atomwise's CBO, making it a closely comparable business model and direct competitor for pharma BD.

TypeDirect peer
Description

AI-driven precision medicine company using a Centaur Chemist™ platform for small molecule design. Comparable as an AI-first small molecule discovery peer pursuing pharma partnerships and an internal pipeline.

TypeDirect peer
Description

Physics-based computational chemistry platform for molecular design, combined with an internal therapeutics pipeline. Highly comparable to DeepCure's use of quantum mechanical and molecular dynamics methods in PocketExpander.

TypeDirect peer
Description

End-to-end AI-driven drug discovery company combining generative chemistry, target ID, and automated biology. Most directly comparable to DeepCure as a fellow AI-native small molecule discovery platform pursuing IND-ready candidates.

TypeDirect peer
Description

AI drug discovery company combining knowledge graphs and ML for target ID and small molecule discovery. Comparable as a platform-first discovery company with therapeutic programs in immunology/inflammation-adjacent areas.

TypeDirect peer
Description

AI + physics-based drug discovery company combining quantum physics, cloud computing, and robotic synthesis. Comparable end-to-end platform architecture and emphasis on automation in compound generation.

TypeBroad incumbent
Description

Flagship Pioneering–backed generative AI biology company designing novel therapeutics. Operates at broader scale and across modalities, but competes for the same pharma BD mindshare and validates the AI-discovery category.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput wet-lab experimentation with machine learning. Comparable as a technology-first discovery company advancing internal pipeline candidates through preclinical and clinical stages.

TypeEmerging player
Description

AI protein design and engineering company with generative models for biologics. Less directly overlapping (biologics vs. DeepCure's small molecules), but a comparable AI-native discovery company targeting pharma BD.

10Isomorphic Labs
TypeEmerging player
Description

Alphabet-founded AI drug design company applying DeepMind protein-modeling breakthroughs to small molecule design. Emerging competitor with comparable AI-physics approach but deeper capital and pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DeepCure

Biotechnology / AI-driven small molecule drug discoverydeepcure.com

DeepCure is a Boston-based, pre-revenue biotech that uses an integrated AI, physics-based, and automated chemistry platform (PocketExpander, MolGen, DiscoveryHub, Inspired Chemistry) to discover oral small molecule drugs for immune and inflammatory diseases, pursuing a licensing and co-development model with pharmaceutical partners.

What DeepCure does

DeepCure is a privately held, Boston-headquartered biotechnology company developing AI-driven small molecule therapeutics for immune and inflammatory diseases. Its integrated platform, branded Inspired Chemistry, combines three proprietary components: PocketExpander, which uses AI plus quantum-mechanical and molecular dynamics simulations to map protein surfaces and identify druggable features on targets without known ligands; MolGen, a deep reinforcement learning system that generates readily synthesizable compounds across millions of building blocks and more than 200 chemical reactions; and DiscoveryHub, a collaborative DMTA workflow layer. The platform is closed-loop with an automated robotic wet lab (the Inspired Chemistry synthesis module, built in partnership with Biosero) that has demonstrated parallel synthesis of nirmatrelvir plus 56 analogs.

The company's pipeline comprises three oral small molecule programs: DC-9476, a third-generation selective BRD4-BD2 inhibitor in IND-enabling studies for rheumatoid arthritis, Still's disease, and hidradenitis suppurativa; DC-15442, an oral STAT6 inhibitor named as a development candidate in June 2025 for asthma and atopic dermatitis with preclinical efficacy comparable to dupilumab; and an early-discovery TNFα program for autoimmune indications. DeepCure has also extended its AI stack into knowledge retrieval through a chemistry LLM workflow developed with Google Cloud Platform and CloudWerx, and is generating clinical evidence via a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine.

DeepCure is pre-revenue and pursues a licensing and co-development business model targeting pharmaceutical and biotech partners. The company has raised approximately $70.4 million across seed, Series A, and Series A-1 rounds from investors including Morningside Ventures, TLV Partners, Sapir Venture Partners, Benon Group, and IAG Capital Partners, with Series A proceeds earmarked for establishing operations in Greece and Israel. Its go-to-market is enterprise business development led by CBO Han Lim (formerly CBO of Atomwise), supported by scientific thought leadership at industry conferences and preclinical data publications.

DeepCure firmographics

Firmographics
Name
DeepCure
Legal name
Deepcure
Website
https://deepcure.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
DeepCure is a Boston-based, pre-revenue biotech that uses an integrated AI, physics-based, and automated chemistry platform (PocketExpander, MolGen, DiscoveryHub, Inspired Chemistry) to discover oral small molecule drugs for immune and inflammatory diseases, pursuing a licensing and co-development model with pharmaceutical partners.
Ownership category
akta.pro rank

DeepCure industry classification

Industry
Product category
Biotechnology / AI-driven small molecule drug discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Small molecule therapeutics
  • Computational chemistry
  • Inflammatory disease pipeline
  • Preclinical immunology

Where DeepCure is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices4 records

Markets served

DeepCure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

  1. Therapeutic Development & Licensing: DeepCure is a pre-revenue biotech company developing a pipeline of novel small molecule drugs for immune and inflammatory diseases. Its primary anticipated revenue streams are out-licensing deals, co-development partnerships with pharmaceutical companies, and ultimately product approvals. The company is advancing DC-9476 (BRD4-BD2 inhibitor, IND-enabling for RA, Still's disease, hidradenitis suppurativa) and DC-15442 (STAT6 inhibitor, development candidate for asthma, atopic dermatitis), with a TNFα program in early discovery.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

DeepCure product offering

Product offering

Core offering

DeepCure uses AI and physics-based computational methods to discover and develop novel oral small molecule therapeutics for immune and inflammatory diseases, integrating molecular generation, protein surface mapping, and automated robotic synthesis into a single drug discovery platform. Its current product offering consists of a pipeline of preclinical and IND-enabling drug candidates (DC-9476 for autoimmune diseases, DC-15442 for asthma/atopic dermatitis, and a TNFα program) that it out-licenses or co-develops with pharmaceutical partners. The company does not sell commercial products directly and is pre-revenue, relying on licensing deals, co-development partnerships, and potential acquisitions.

Product overview

DeepCure is an immunology therapeutics company developing novel small molecule drugs for immune and inflammatory diseases using an integrated AI-powered drug discovery platform called Inspired Chemistry. The platform comprises three core proprietary technologies: PocketExpander (AI and physics-based protein surface mapping), MolGen (reinforcement learning-driven molecular generation), and DiscoveryHub (collaborative research workflow management). The company is advancing a pipeline of oral small molecule therapeutics including DC-9476 (BRD4-BD2 inhibitor for rheumatoid arthritis, IND-enabling stage) and DC-15442 (STAT6 inhibitor for asthma/atopic dermatitis, development candidate stage), with a TNFα program in early discovery. DeepCure operates from Boston with R&D sites in Israel and Greece.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • DC-15442 demonstrated nearly 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab in preclinical models
  • +2 more outcomes

Companies that use DeepCure

Customer profile

Segments2 records

Ideal customer profiles1 record

DeepCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

DeepCure partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Google Cloud Platform (GCP)coreTechnology or Integration · 3 March 2025DeepCure completed a pilot program with Google Cloud Platform and CloudWerx (CWX) to build an AI-driven workflow that extracts chemical insights from unstructured literature to answer complex queries on organic chemistry, demonstrating the potential for chemistry LLMs to increase productivity in medicinal chemistry.
  • CloudWerx (CWX)coreTechnology or Integration · 3 March 2025CloudWerx collaborated with DeepCure and Google Cloud Platform to build an AI-driven workflow for extracting chemical insights from unstructured literature, demonstrating chemistry LLM capabilities for medicinal chemistry productivity.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)coreStrategic or Co-development Partner · 19 August 2024DeepCure announced a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine to investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for rheumatoid arthritis patients who do not respond well to current standard of care. The partners will conduct a study using blood samples and joint biopsies from various patient subgroups, focusing on those resistant to current treatments.
  • BioserocoreTechnology or Integration · 5 January 2023DeepCure and Biosero collaborated to establish a fully automated, AI-powered chemistry synthesis platform. This collaboration enabled DeepCure to accelerate synthesis of AI-designed molecules and validate its Inspired Chemistry™ platform.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

DeepCure competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI small molecule discovery platform using structure-based deep learning for hit identification and lead optimization. DeepCure's CBO previously served as Atomwise's CBO, making it a closely comparable business model and direct competitor for pharma BD.
  • Exscientia: AI-driven precision medicine company using a Centaur Chemist™ platform for small molecule design. Comparable as an AI-first small molecule discovery peer pursuing pharma partnerships and an internal pipeline.
  • Schrödinger: Physics-based computational chemistry platform for molecular design, combined with an internal therapeutics pipeline. Highly comparable to DeepCure's use of quantum mechanical and molecular dynamics methods in PocketExpander.
  • Insilico Medicine: End-to-end AI-driven drug discovery company combining generative chemistry, target ID, and automated biology. Most directly comparable to DeepCure as a fellow AI-native small molecule discovery platform pursuing IND-ready candidates.
  • BenevolentAI: AI drug discovery company combining knowledge graphs and ML for target ID and small molecule discovery. Comparable as a platform-first discovery company with therapeutic programs in immunology/inflammation-adjacent areas.
  • XtalPi: AI + physics-based drug discovery company combining quantum physics, cloud computing, and robotic synthesis. Comparable end-to-end platform architecture and emphasis on automation in compound generation.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput wet-lab experimentation with machine learning. Comparable as a technology-first discovery company advancing internal pipeline candidates through preclinical and clinical stages.

Broad incumbents

  • Generate:Biomedicines: Flagship Pioneering–backed generative AI biology company designing novel therapeutics. Operates at broader scale and across modalities, but competes for the same pharma BD mindshare and validates the AI-discovery category.

Emerging players

  • Cradle Bio: AI protein design and engineering company with generative models for biologics. Less directly overlapping (biologics vs. DeepCure's small molecules), but a comparable AI-native discovery company targeting pharma BD.
  • Isomorphic Labs: Alphabet-founded AI drug design company applying DeepMind protein-modeling breakthroughs to small molecule design. Emerging competitor with comparable AI-physics approach but deeper capital and pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

DeepCure social profiles

Digital presence

DeepCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DeepCure leadership team

Management profile

Number of profiles

Profiles7 records

DeepCure funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DeepCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepCure

What does DeepCure do?

DeepCure uses AI and physics-based computational methods to discover and develop novel oral small molecule therapeutics for immune and inflammatory diseases, integrating molecular generation, protein surface mapping, and automated robotic synthesis into a single drug discovery platform. Its current product offering consists of a pipeline of preclinical and IND-enabling drug candidates (DC-9476 for autoimmune diseases, DC-15442 for asthma/atopic dermatitis, and a TNFα program) that it out-licenses or co-develops with pharmaceutical partners. The company does not sell commercial products directly and is pre-revenue, relying on licensing deals, co-development partnerships, and potential acquisitions.

Is DeepCure a public or private company?

DeepCure is a private company. It is classified as venture growth investor backed and is currently operating.

When was DeepCure founded?

DeepCure was founded in 2020. It employs 11 to 50 people.

Where is DeepCure based?

DeepCure is headquartered in Boston, United States, in the North America region.

How does DeepCure make money?

One revenue line is on record: therapeutic Development & Licensing.

Who are DeepCure's main competitors?

Direct peers on record are Atomwise, Exscientia, Schrödinger, Insilico Medicine, BenevolentAI, XtalPi and Recursion Pharmaceuticals. Generate:Biomedicines is listed as a broad incumbent. Emerging players are Cradle Bio and Isomorphic Labs.

Does DeepCure have an API?

No public API is recorded for DeepCure.

What industry is DeepCure in?

DeepCure's product category is Biotechnology / AI-driven small molecule drug discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease modelsDeepCure announced the nomination of DC-15442 as its second development candidate, an oral STAT6 inhibitor designed to be a safe alternative to dupilumab for treating various inflammatory conditions. The drug demonstrates near-complete inhibition of pSTAT6 and effectiveness comparable to dupilumab in preclinical models, with a favorable safety profile. The company aims to expand treatment options for patients requiring chronic therapies.PatsnapDrug pipelines, Patents, Clinical trialsDeepCure, a Boston-based AI therapeutics company, announced the discovery of potent, selective oral small molecule STAT6 inhibitors for type 2 inflammatory diseases, with plans to select a development candidate and enter IND-enabling studies. Separately, Gilead Sciences and LEO Pharma entered a strategic partnership worth up to $1.7 billion, with Gilead gaining global rights to LEO Pharma's oral STAT6 inhibitors while LEO Pharma retains co-commercialization rights for dermatological indications outside the U.S. and rights to topical formulations. The STAT6 inhibitor space is emerging as a competitive battleground among major pharmaceutical companies including Johnson & Johnson, Sanofi, and AstraZeneca, with multiple candidates in various stages of preclinical and clinical development.PixelscientiaAdvancing Therapies for Immune Diseases with Kfir Schreiber from DeepCureDeepCure, an AI-driven drug discovery startup, is advancing therapies for immune diseases by combining machine learning with physics-based simulations and human expertise to design small molecule drugs. The company has a lead program targeting rheumatoid arthritis that is nearing clinical trials, with additional programs for asthma in development. DeepCure aims to approach regulatory approval for its first drug within five years while expanding its pipeline to treat other autoimmune conditions.TmcnetDeepCure Announces Selection of First AI-Generated Candidate DC-9476 for Autoimmune DiseasesDeepCure announced its first AI-generated development candidate, DC-9476, a third-generation BRD inhibitor selective for the BD2 domain of Brd4, expected to enter clinical trials in 2025. The compound showed superior efficacy in rheumatoid arthritis and Still's disease models and an excellent safety profile. The company plans to advance it into clinical trials next year.YahooDeepCure Announces Selection of First AI-Generated Candidate DC-9476 for Autoimmune DiseasesDeepCure announced its first AI-generated development candidate, DC-9476, a third-generation BRD inhibitor selective for the BD2 domain of Brd4. The compound showed superior efficacy in rheumatoid arthritis and Still's disease models and is expected to enter clinical trials in 2025.TmcnetDeepCure Turns Complex Drug Designs into Testable Molecules with Robotic Synthesis BreakthroughDeepCure announced its Inspired Chemistry platform synthesized nirmatrelvir and 56 analogs in parallel using a robot-driven workflow. The synthesis yielded 30 mg of nirmatrelvir at 98% purity and over 50 diverse analogs at 1 mg scale. The platform is available to early access partners and aims to accelerate drug discovery.Business Wire BlogDeepCure Turns Complex Drug Designs into Testable Molecules with Robotic Synthesis BreakthroughDeepCure announced its Inspired Chemistry platform synthesized nirmatrelvir and 56 analogs in parallel using a robot-driven workflow. The synthesis yielded 30 mg of nirmatrelvir at 98% purity and over 50 diverse analogs at 1 mg scale. The platform is available to early access partners and aims to accelerate drug discovery.The SaaS NewsDeepCure Raises $24.6 Million in Series A-1 RoundDeepCure, a Boston-based company developing AI-driven small molecule therapeutics, has raised $24.6 million in a Series A-1 funding round led by IAG Capital Partners. This latest investment brings the company's total capitalization to over $72 million as it continues to advance its immunology and inflammation pipeline toward clinical trials.Pulse 2.0DeepCure: Small Molecule Therapeutics Company Raises $24 MillionDeepCure announced the closing of a $24.6 million Series A-1 financing round led by IAG Capital Partners with participation from existing investors. The company, which utilizes AI and chemistry automation for drug discovery, plans to use these proceeds to advance its immunology and inflammation pipeline toward clinical trials.VC News DailyVenture Capital News: DeepCure Grabs $24.6M Series A-1DeepCure, an AI-driven drug discovery company based in Boston, closed a $24.6 million Series A-1 financing round led by IAG Capital Partners. This latest investment brings the total capital raised by the company to over $72 million since its inception. The funding will support DeepCure's efforts to accelerate the development of novel small molecule therapeutics using artificial intelligence and automation.